Evidence map›Paper›PMID 32399804›Full record

ReviewNeuromolecular medicine2021

Application of Next-Generation Sequencing in Neurodegenerative Diseases: Opportunities and Challenges.

Behrouz Shademan, Cigir Biray Avci, Masoud Nikanfar, Alireza Nourazarian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Behrouz ShademanDepartment of Medical Biology, Medical Faculty, Ege University, 35100, Bornova, Izmir, Turkey.
Cigir Biray Avci *Department of Medical Biology, Medical Faculty, Ege University, 35100, Bornova, Izmir, Turkey. cbavci@gmail.com.
Masoud NikanfarDepartment of Neurology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Alireza NourazarianDepartment of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Golgasht St., 51666-16471, Tabriz, Iran. Nourazariana@tbzmed.ac.ir.ORCID 0000-0003-2082-1335
Ege University · TRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic factors (gene mutations) lead to various rare and prevalent neurological diseases. Identification of underlying mutations in neurodegenerative diseases is of paramount importance due to the heterogeneous nature of the genome and different clinical manifestations. An early and accurate molecular diagnosis are cardinal for neurodegenerative patients to undergo proper therapeutic regimens. The next-generation sequencing (NGS) method examines up to millions of sequences at a time. As a result, the rare molecular diagnoses, previously presented with "unknown causes", are now possible in a short time. This method generates a large amount of data that can be utilized in patient management. Since each person has a unique genome, the NGS has transformed diagnostic and therapeutic strategies into sequencing and individual genomic mapping. However, this method has disadvantages like other diagnostic methods. Therefore, in this review, we aimed to briefly summarize the NGS method and correlated studies to unravel the genetic causes of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, epilepsy, and MS. Finally, we discuss the NGS challenges and opportunities in neurodegenerative diseases.

Indexed as

High-Throughput Nucleotide SequencingAlzheimer DiseaseBase SequenceEarly DiagnosisEpilepsyExome SequencingForecastingGene LibraryGenetic HeterogeneityGenetic Predisposition to DiseaseGenetic TestingHumansMolecular Diagnostic TechniquesMultiple SclerosisNeurodegenerative DiseasesParkinson DiseaseGene panelNeurological diseasesNext-generation sequencing (NGS)Whole exome sequencing (WES)Whole genome sequencing (WGS)

Identifiers

PMID32399804
OpenAlexW3024598470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.